Business Segments · Restructuring (Note 12)
MEDTECH — Restructuring (Note 12)
Johnson & Johnson MEDTECH — Restructuring (Note 12) decreased by 50.0% to $100.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 81.8%, from $55.00M to $100.00M. Over 3 years (FY 2021 to FY 2025), MEDTECH — Restructuring (Note 12) shows an upward trend with a 11.5% CAGR.
Analysis
StatementSegment
CategoryEfficiency
SignalContext dependent
VolatilityVolatile
First reportedQ4 2015
Last reportedQ1 2026Apr 22, 2026
Rolls up toRestructuring Charges
How to read this metric
High restructuring costs indicate active efforts to improve efficiency, which may lead to future margin improvements.
Detailed definition
This metric tracks the costs associated with reorganizing the medical technology segment's operations, such as workforce...
Peer comparison
Commonly reported by large-cap companies undergoing periodic operational transformation.
Metric ID:
jnj_segment_medtech_restructuring_note_12Historical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $100.00M | $100.00M | $100.00M | $100.00M | $100.00M | $100.00M | $100.00M | $235.00M | $84.00M | $27.00M | $100.00M | $28.00M | $93.00M | $55.00M | $100.00M | $200.00M | $200.00M | $100.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +135.0% | -64.3% | -67.9% | +270.4% | -72.0% | +232.1% | -40.9% | +81.8% | +100.0% | +0.0% | -50.0% |
| YoY Change | — | — | — | — | +0.0% | +0.0% | +0.0% | +135.0% | -16.0% | — | — | -88.1% | +10.7% | +103.7% | +0.0% | +614.3% | +115.1% | +81.8% |
Range$27.00M – $235.00M
CAGR+0.0%
Avg YoY Growth+79.7%
Median YoY Growth+5.4%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's medtech — restructuring (note 12)?
- Johnson & Johnson (JNJ) reported medtech — restructuring (note 12) of $100.00M in Q1 2026.
- How has Johnson & Johnson's medtech — restructuring (note 12) changed year-over-year?
- Johnson & Johnson's medtech — restructuring (note 12) increased by 81.8% year-over-year, from $55.00M to $100.00M.
- What is the long-term trend for Johnson & Johnson's medtech — restructuring (note 12)?
- Over 3 years (2021 to 2025), Johnson & Johnson's medtech — restructuring (note 12) has grown at a 11.5% compound annual growth rate (CAGR), from $400.00M to $555.00M.
- What does medtech — restructuring (note 12) mean?
- Costs incurred to reorganize or streamline the medical technology business operations.